1.50 / AMA PRA Category 1 Credit(s)TM 1.75 / CE for Pharmacists (0.175 CEUs)
Jointly provided/Co-sponsored by Haymarket Medical Education and Postgraduate Institute for Medicine
Supported by educational grants from Allergan, Inc., Ironwood Pharmaceuticals, and Synergy Pharmaceuticals Inc.
Irritable bowel syndrome (IBS) affects 10% to 20% of the general American adult population and accounts for up to 40% of visits to gastroenterology practices. Because management of IBS remains a challenge for many clinicians, the goal of this program is to improve the ability of gastroenterologists to make individualized diagnostic and treatment decisions for patients with IBS. Through faculty presentations and open faculty discussion, issues surrounding the pathophysiology of IBS, establishing a diagnosis with clinical algorithms using Rome IV criteria, and developing treatment strategies based on multidimensional clinical profiles will be addressed. In addition, a video emphasizing “A Day in the Life” will present the patient perspective of having IBS and the impact that it has on quality of life.
Gastroenterologists, pharmacists, and other healthcare professionals who manage patients with IBS
At the conclusion of this activity, participants should be better able to:
Accurately diagnose patients with irritable bowel syndrome with constipation (IBS-C) and IBS with diarrhea (IBS-D) by eliciting a thorough patient history and utilizing clinical criteria
Tailor treatment options for patients based on their predominant symptoms while considering the mechanisms of action and potential side effects of each treatment
Implement patient-centric care plans for managing IBS symptoms and improving patients’ overall quality of life
As part of the treatment team, provide accurate and appropriate counsel to patients with IBS symptoms
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Douglas A. Drossman, MD (Chair) President, Rome Foundation Professor Emeritus of Medicine and Psychiatry University of North Carolina at Chapel Hill Director, Drossman Center for Education and Practice of Biopsychosocial Care Drossman Gastroenterology, PLLC Chapel Hill, NC
Dr. Drossman is a consultant for Synergy Pharmaceuticals Inc.
Brian E. Lacy, MD, PhD Co-chair, Rome IV Bowel Committee Professor of Medicine Geisel School of Medicine at Dartmouth Chief, Section of Gastroenterology and Hepatology Dartmouth-Hitchcock Medical Center Lebanon, NH
Dr. Lacy is a consultant for Ironwood Pharmaceuticals, Salix Pharmaceuticals, and Synergy Pharmaceuticals Inc. He is also the lead investigator for research funded by Takeda Pharmaceuticals.
Anthony J. Lembo, MD Member, Rome IV Bowel Committee Associate Professor of Medicine Harvard Medical School Boston, MA
Dr. Lembo is a consultant for Allergan, Inc., Ardelyx, Ironwood Pharmaceuticals, Prometheus Laboratories Inc., Salix Pharmaceuticals, and Valeant Pharmaceuticals International, Inc. He is also the lead investigator for research funded by Prometheus Laboratories Inc.
Magnus Simrén, MD, PhD Rome Foundation Board of Directors Member, Rome IV Bowel Committee Professor, Consultant Department of Internal Medicine & Clinical Nutrition Institute of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden
Dr. Simrén is a consultant for Almirall, Allergan, Inc., Albireo, AstraZeneca, Danone, Chr Hansen Holding A/S, Glycom, Nestlé, and Shire. He is on the speakers’ bureaus of Almirall, Shire, Takeda Pharmaceuticals, and Tillotts Pharma AG. Dr. Simrén is also the lead investigator for unrestricted research funded by Danone and Ferring Pharmaceuticals.
Accredited Provider Disclosure
The Haymarket Medical Education staff involved in the planning and content review have no relevant financial relationships to disclose.
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only those credits commensurate with the extent of their participation in the activity.
CE for Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Universal Activity Number - 0809-9999-16-453-H01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Allergan, Inc., Ironwood Pharmaceuticals, Synergy Pharmaceuticals Inc., Haymarket Medical Education, and the Postgraduate Institute for Medicine do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Allergan, Inc., Ironwood Pharmaceuticals, Synergy Pharmaceuticals Inc., Haymarket Medical Education, and the Postgraduate Institute for Medicine. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
If you have any questions relating to the CPE certification of this activity, please contact email@example.com.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.